KR20160079607A - Composition for anti-inflammation or immuno-stimulation containing an extract of a nut pine cone - Google Patents
Composition for anti-inflammation or immuno-stimulation containing an extract of a nut pine cone Download PDFInfo
- Publication number
- KR20160079607A KR20160079607A KR1020150084425A KR20150084425A KR20160079607A KR 20160079607 A KR20160079607 A KR 20160079607A KR 1020150084425 A KR1020150084425 A KR 1020150084425A KR 20150084425 A KR20150084425 A KR 20150084425A KR 20160079607 A KR20160079607 A KR 20160079607A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- picea
- water
- tnf
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 131
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract description 15
- 206010061218 Inflammation Diseases 0.000 title abstract description 9
- 244000098674 Pinus cembroides Species 0.000 title 1
- 235000005013 Pinus cembroides Nutrition 0.000 title 1
- 235000008591 Pinus cembroides var edulis Nutrition 0.000 title 1
- 235000015593 Pinus monophylla Nutrition 0.000 title 1
- 235000015594 Pinus parryana Nutrition 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims abstract description 27
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 24
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 17
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 17
- 241000972672 Phellodendron Species 0.000 claims abstract description 11
- 239000003022 immunostimulating agent Substances 0.000 claims abstract description 8
- 229960001438 immunostimulant agent Drugs 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 241000218657 Picea Species 0.000 claims description 32
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 11
- 244000184734 Pyrus japonica Species 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 240000000491 Corchorus aestuans Species 0.000 claims 1
- 235000011777 Corchorus aestuans Nutrition 0.000 claims 1
- 235000010862 Corchorus capsularis Nutrition 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 abstract description 16
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 5
- 230000001988 toxicity Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 235000011613 Pinus brutia Nutrition 0.000 description 31
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 30
- 241000018646 Pinus brutia Species 0.000 description 30
- 238000001035 drying Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 23
- 102100040247 Tumor necrosis factor Human genes 0.000 description 20
- 238000009472 formulation Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 239000010903 husk Substances 0.000 description 15
- 240000007594 Oryza sativa Species 0.000 description 14
- 235000007164 Oryza sativa Nutrition 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 235000009566 rice Nutrition 0.000 description 14
- 239000000469 ethanolic extract Substances 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 239000006227 byproduct Substances 0.000 description 11
- -1 ethyl oleate Chemical class 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 241000219130 Cucurbita pepo subsp. pepo Species 0.000 description 5
- 235000003954 Cucurbita pepo var melopepo Nutrition 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 3
- 244000300264 Spinacia oleracea Species 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- DELJNDWGTWHHFA-UHFFFAOYSA-N 1-azaniumylpropyl(hydroxy)phosphinate Chemical compound CCC(N)P(O)(O)=O DELJNDWGTWHHFA-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 241000722921 Tulipa gesneriana Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 235000013736 caramel Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 235000020737 peppermint extract Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000020712 soy bean extract Nutrition 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001362614 Crassa Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001463064 Junea Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 240000007263 Pinus koraiensis Species 0.000 description 1
- 235000011615 Pinus koraiensis Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- ZMZINYUKVRMNTG-UHFFFAOYSA-N acetic acid;formic acid Chemical compound OC=O.CC(O)=O ZMZINYUKVRMNTG-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940111793 eggplant extract Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000008269 hand cream Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The anti-inflammatory composition comprising the extract of Phellodendrons as an effective ingredient disclosed in this specification can effectively alleviate, treat or prevent inflammation by effectively inhibiting the production of NO and TNF-? Without toxicity. In addition, the immunostimulant composition comprising the extract of Phellodendrons as an effective ingredient disclosed in this specification can exhibit an effective immune enhancing effect by effectively proliferating macrophages and enhancing the expression or activity of IL-6 without toxicity.
Description
The present specification relates to the anti-inflammatory or immunostimulatory use of the extract of Picea magna.
Pinus koraiensis, also called a sea-son, belongs to Pinaceae. In pine nut seeds, 62.2% ~ 74.0% of fat is the most abundant, 16.4% is the protein, and other abundant inorganic minerals and vitamins such as carbohydrates and phosphorus. In addition, the leaf of the pine tree contains two alkaloid components, pichecoline and pyrene.
Many seeds of pine trees and plants come into seed pine, called pine cones, and the pine cones are called "pine nuts" in particular. Pine cones, including pine nuts, are used as a way to drink and soak up a unique flavor in a drink. In addition, although fully ripened pine nut is removed from the shell and used as a material for various foods, it is used as a feed for livestock such as pigs or fermented parts, (Korean Patent No. 10-2012-0106848), but most of them are being abandoned.
However, it is very difficult to dispose of pine nuts without using them because the pine nuts contain a considerable amount of essential oil components and other oil components that give off the pine nut aroma and contain a large amount of components that act pharmacologically, such as pine nut and pine nut. , One of the important forest resources, pine trees, is not yet fully utilized, and a method is needed that can be used more usefully.
In one aspect, the object is to enhance immunity.
In another aspect, the object is to alleviate, treat, or prevent inflammation.
In one aspect, the present invention provides an immunostimulant composition comprising an extract of Phellodendron as an active ingredient.
In another aspect, the extract of the rice husk may be one that promotes the proliferation of immune cells.
In another aspect, the extract may be one that promotes the expression or activity of IL-6.
In one aspect, the present invention provides a anti-inflammatory composition comprising the extract of Picea magna as an active ingredient.
In another aspect, the extract of Picea japonica may inhibit the excessive production of NO and TNF-a.
In another aspect, the extract of Picea may be water or an extract of lower alcohol.
In another aspect, the extract of Pyralpine sp. May be an extract of ultrapure water or an aqueous solution of ethanol.
In another aspect, the extract of Picea may be an extract of Picea peel.
In one aspect, the composition of the present invention may be a cosmetic, a food or a pharmaceutical composition.
In one aspect, the anti-inflammatory or immunostimulating effect can be effectively obtained without toxicity.
It is possible to recycle the pellets that are discarded from the other side, thereby achieving the effect of resource saving or environmental protection.
Fig. 1 is a view showing a process for manufacturing a rice husk extract (at the time of 2L production).
FIG. 2 is a graph showing the cytotoxicity measurement results of the extract of Picea magna.
FIG. 3 is a graph showing the results of experiments for inhibiting the NO production ability of the extract of Picea magnesia.
Fig. 4 is a graph showing the results of measurement of TNF-a of the extract of Picea magnesia.
FIG. 5 is a graph showing the results of measurement of IL-6 activity of the extract of Picea magna.
FIG. 6 is a graph showing changes in the amount of TNF-.alpha.
FIG. 7 is a graph showing changes in IL-6 in mouse murine macrophages treated with the extract of Picea tulip.
FIG. 8 is a graph showing the effect of the extract of the rice husk on the proliferation of splenocytes.
In one aspect of the present invention, there is provided an immunostimulant composition comprising an extract of Picea magna as an active ingredient.
In the immunostimulant composition according to one aspect of the present invention, the extract of Picea may be an immunostimulating agent composition for promoting the proliferation of immune cells.
In one aspect of the present invention, the egg plant extract may be an immunostimulant composition that promotes the expression or activity of IL-6.
In one aspect of the present invention, there is provided a anti-inflammatory composition comprising the extract of Picea magna as an active ingredient.
In the anti-inflammatory composition according to one aspect of the present invention, the extract of Picea Capsicum may be a anti-inflammatory composition inhibiting the excessive production of NO and TNF- ?.
In the anti-inflammatory composition according to one aspect of the present invention, the extract of Zucchini spinach may be a composition which is an extract of water or a lower alcohol, specifically, a composition that is an extract of ultrapure water or an aqueous solution of ethanol.
In one aspect of the present invention, the immunostimulant or anti-inflammatory composition may be a composition that is an extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of the extract of P. japonica.
In one embodiment of the present invention, the present invention is a composition comprising an extract of Peppermint roots as an active ingredient.
As used herein, the term " extract " is a broad concept that encompasses all of the substances obtained by extracting components of natural products, regardless of the type of extraction method, extraction solvent, extracted component or extract.
In one aspect of the present invention, a method for preparing the extract of Picea Capsicum is as follows, but a conventional extraction method can be used, and the scope of the present invention is not limited thereto.
A method for preparing a rice husk extract, comprising the steps of: preparing a raw material for rice husk or rice husk by-products; Drying the raw material; And extracting the dried raw material with a solvent.
In one aspect of the present invention, the pine nut of the step of preparing the raw materials of the pine nut or the pine nut byproduct may be a pine nut of the common pine tree. The by-product of the pine nut is a by-product generated in the process of producing pine nut in the pine nut, Shells and the like. The raw material may be at least one selected from the group consisting of pine nut and pellet by-products. In the case of using the pine nut by-products in one aspect, the pine nut in the process of producing pine nut to obtain pine nut in the pine nut is recycled, It is effective.
In one aspect of the present invention, the step of drying the raw material comprises a one-stage drying step and may be carried out at a temperature of 40 ° C to 500 ° C for 1 minute to 240 hours.
In one embodiment, the drying step may comprise a primary, secondary, tertiary or quaternary drying step. The drying step may proceed to an appropriate order until the moisture is sufficiently dried.
In one embodiment, the temperature of the drying step is greater than or equal to 40 ° C, greater than or equal to 45 ° C, greater than or equal to 50 ° C, greater than or equal to 60 ° C, greater than or equal to 65 ° C, greater than or equal to 70 ° C, , 95 占 폚 or higher, 100 占 폚 or higher, or 105 占 폚 or higher.
In one embodiment, the temperature of the drying step may be less than 500 ° C, less than 450 ° C, less than 400 ° C, less than 350 ° C, less than 300 ° C, less than 250 ° C, less than 200 ° C, less than 150 ° C, or less than 105 ° C.
When the temperature of the drying step is within the above-mentioned range, sufficient drying is performed to increase the anti-inflammatory or immunological activity in the production of the extract of the pressed rice husk.
In one embodiment, the drying time is at least 1 minute, at least 5 minutes, at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 40 minutes, at least 50 minutes, at least 1 hour, at least 2 hours, Hour, more than 5 hours, more than 6 hours, more than 12 hours, and more than 24 hours.
In one embodiment, the drying time may be 240 hours or less, 216 hours or less, 192 hours or less, 168 hours or less, 144 hours or less, 120 hours or less, 96 hours or less, 72 hours or 48 hours or less.
When the drying time in the drying step is within the above range, sufficient drying is performed to increase the anti-inflammatory or immunological activity in the production of the extract.
In one aspect of the present invention, the step of extracting the dried raw material may be performed by extracting the dried raw material with one or more selected from the group consisting of water, an organic solvent, and a mixture of water and an organic solvent. The organic solvent includes, but is not limited to, at least one selected from the group consisting of alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform. Wherein the alcohol comprises a C 1 to C 5 lower alcohol and the C 1 to C 5 lower alcohol is selected from the group consisting of methanol, ethanol, isopropyl alcohol, n-propyl alcohol, n-butanol and isobutanol But is not limited thereto.
In one embodiment, the water may be ultra-pure water.
In one embodiment, the organic solvent may be ethanol.
In one embodiment, the mixture of water and an organic solvent may be an aqueous solution of ethanol.
In one embodiment, the concentration of the aqueous ethanol solution is at least 0.01%, at least 0.1%, at least 1%, at least 5%, at least 10%, at least 15%, at least 20% 30 wt% or more, 35 wt% or more, 40 wt% or more, 45 wt% or more, or 50 wt% or more.
In one embodiment, the concentration of the aqueous ethanol solution may be up to 100 wt%, up to 90 wt%, up to 80 wt%, up to 70 wt%, or up to 60 wt%.
When the concentration of the aqueous ethanol solution is within the above range, the anti-inflammatory or immunological activity is increased in the production of the extract.
In one aspect of the present invention, the step of extracting the dried raw material may include a step of concentration under reduced pressure and a freeze-drying step.
In one embodiment, the reduced pressure concentration can be reduced to a pressure of 5 to 50 brix at a temperature of 40 to 90 占 폚.
In one embodiment, the temperature of the reduced pressure concentration may be at least 40 ° C, at least 45 ° C, or at least 50 ° C.
In one embodiment, the temperature for the reduced pressure concentration may be 90 ° C or lower, 85 ° C or lower, 80 ° C or lower, 75 ° C or lower, 70 ° C or lower, 65 ° C or lower, 60 ° C or 55 ° C or lower.
When the concentration under reduced pressure is within the above range, the anti-inflammatory or immunological activity is increased in the production of the extract of the rice husk.
The extract of the rice husk produced through the above-mentioned production process has an anti-inflammatory or immunological activity effect.
In one aspect of the present invention, there is provided a composition comprising, as an active ingredient, a rice husk extract having anti-inflammatory or immunostimulatory activity.
In one embodiment, the extract of Pyranthaioptera canis is at least 10 ug / mL, at least 20 / / mL, at least 30 / / mL, at least 40 / / mL, at least 50 / / mL, at least 100 / / ML or more, 250 μg / mL or more, 300 μg / mL or more, 350 μg / mL or more, 400 μg / mL or more, 450 μg / mL or more, mL or more, 700 μg / mL or more, 800 μg / mL or more, 900 μg / mL or more, or 1000 μg / mL or more.
In one embodiment, the Yatch Rice extract may be 100,000 g / mL or less, 50,000 g / mL or less, 10,000 g / mL or less and 5000 g / mL or less based on the total composition.
When the extract of Picea zodiaca is contained within the above range, the anti-inflammatory or immunostimulating effect can be effectively obtained without toxicity.
In one embodiment, the extract is a water-extracted extract, wherein the extract is at least 10 / / mL, at least 20 / / mL, at least 30 / / mL, at least 40 / / mL, at least 50 / / mL ML, at least 150 μg / mL, at least 200 μg / mL, at least 250 μg / mL, at least 300 μg / mL, at least 350 μg / mL, at least 400 μg / ML or more, 600 μg / mL or more, 700 μg / mL or more, 800 μg / mL or more, 900 μg / mL or more or 1000 μg / mL or more.
In one embodiment, the Peppermint Water Extract may be less than 100,000 g / mL, less than 50,000 g / mL, less than 10,000 g / mL, and less than 5000 g / mL, based on the total composition.
When the water extract of Peppermint Water is contained within the above range, the anti-inflammatory or immunostimulating effect can be effectively obtained without toxicity. Specifically, when the water extract of Picea juncea is within the above-mentioned range, IL-1 is effectively inhibited by inducing NO or TNF-? Generated by induction of inflammatory reaction, and is also effective as a cytokine that activates NK cells having anti- 6 production, and the production of TNF-a which affects the activity of immune cells is increased, thereby obtaining an immune enhancing effect.
In one embodiment, the composition may be a cosmetic, a food or a pharmaceutical composition.
The composition according to one aspect of the present invention may be a pharmaceutical composition and may be various oral or parenteral formulations. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, soft or hard capsules, etc. These solid preparations may contain one or more excipients such as starch, calcium carbonate, sucrose, Or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
The pharmaceutical dosage forms of the compositions according to one aspect of the present invention may be used in the form of their pharmaceutically acceptable salts and may also be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set. The salt is not particularly limited as long as it is pharmaceutically acceptable so long as it is pharmaceutically acceptable and includes, for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, , Benzenesulfonic acid, toluenesulfonic acid, and naphthalenesulfonic acid.
The composition according to one aspect of the present invention may be administered parenterally or orally, and may be administered in an amount of 0.0001 to 10 g, preferably 0.0001 to 6 g per 1 kg of body weight per day, can do. The dosage for a particular patient may vary depending on the patient's body weight, age, sex, health condition, diet, time of administration, administration method, excretion rate, severity of disease, and the like.
The pharmaceutical composition according to one aspect of the present invention can be administered orally or parenterally in the form of powders, granules, tablets, soft or hard capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations such as ointments, creams, , Injectable solutions, sterile injection solutions, and the like, and may be used in any form suitable for pharmaceutical preparations.
The composition according to one aspect of the present invention can be administered to mammals such as rats, mice, livestock, humans, and the like by various routes such as parenteral, oral, etc. All the ways of administration can be expected, Rectal, rectal or intravenous, intramuscular, subcutaneous, intrauterine or intracerebroventricular injection.
In one aspect of the invention, the food composition may be a health functional food composition.
The formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be formulated into, for example, tablets, granules, powders, liquid preparations such as drinks, caramels, gels, bars and the like. The food composition of each formulation can be blended with the ingredients commonly used in the field in addition to the active ingredient without difficulty by those skilled in the art depending on the purpose of formulation or use, and synergistic effect can be obtained when the composition is applied simultaneously with other ingredients.
In the food composition according to one aspect of the present invention, the determination of the dosage of the active ingredient is within the level of those skilled in the art, and its daily dose is, for example, 0.001 g / kg / day to 10 g / kg / May be 0.1 g / kg / day to 6 g / kg / day, but is not limited thereto, and may vary depending on various factors such as the age, health condition, and complication of the subject to be administered.
The food composition according to one aspect of the present invention can be used in various foods such as chewing gum, caramel product, candy, ice cream, confectionery, beverage such as soft drink, mineral water, alcoholic beverage, health including vitamins and minerals It may be a functional food.
In addition to the above, the food composition which is one aspect of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and enhancers (cheese, chocolate etc.), pectic acid and its salts, Alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the functional food compositions of the present invention may comprise natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally included in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
The formulation of the cosmetic composition according to one aspect of the present invention is not particularly limited and can be appropriately selected according to the purpose. For example, skin lotion, skin softener, skin toner, astringent, lotion, milky lotion, moisturizing lotion, nutrition lotion, massage cream, nutritional cream, moisturizing cream, hand cream, foundation, essence, nutrition essence, pack, soap, cleansing But the present invention is not limited thereto, and may be manufactured by any one or more formulations selected from the group consisting of a foam, a cleansing lotion, a cleansing cream, a body lotion and a body cleanser.
When the formulation of the cosmetic composition according to one aspect of the present invention is a paste, cream or gel, the carrier component may include animal fibers, plant fibers, waxes, paraffins, starch, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, Or zinc oxide may be used.
If the formulation of the cosmetic composition according to one aspect of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component, Propellants such as chlorofluorohydrocarbons, propane / butane or dimethyl ether.
Solvents, solubilizing agents or emulsifying agents are used as carrier components in the case of solutions or emulsions in the form of cosmetic compositions according to one aspect of the present invention, and examples thereof include water, ethanol, isopropanol, ethylcarbonate, ethyl acetate, benzyl alcohol, Benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid esters of sorbitan.
When the formulation of the cosmetic composition according to one aspect of the present invention is a suspension, the carrier component may include water, a liquid diluent such as ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester The same suspending agent, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
When the formulation of the cosmetic composition according to one aspect of the present invention is an interface-active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, , Fatty acid amide ether sulfate, alkylamido betaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolenic derivative, or ethoxylated glycerol fatty acid ester can be used.
The content of the active ingredient is not particularly limited, but may be in the range of 0.001 to 100% by weight based on the total weight of the cosmetic composition according to one aspect of the present invention. When the active ingredient satisfies the above content, it can exhibit excellent efficacy without side effects.
The cosmetic composition may further contain ingredients included in a functional additive and a general cosmetic composition. The functional additives may include water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides, sphingolipids and seaweed extracts.
The cosmetic composition according to one aspect of the present invention may further comprise, in addition to the above-described functional additive, components contained in a general cosmetic composition as required. Examples of the other ingredients that can be included in the composition include humectants, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbents, preservatives, bactericides, antioxidants, plant extracts, pH adjusters, alcohols, Accelerators, coolants, antiperspirants, purified water, and the like.
Hereinafter, the constitution and effects of the present invention will be described in more detail with reference to Examples and Experimental Examples. However, these examples and experimental examples are provided for illustrative purposes only in order to facilitate understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
EXAMPLES Preparation of the extract of rice husk
Preparation
The extracts were collected from Hongcheon County, and the extracts were removed from the pine nuts. The extracts from the forests of Hongcheon County, Gangwon Province were used for the extraction. For the preparation of the extracts, fermented syrup (95%, manufactured by Kohung Life) and ultrapure water (Millipore, MilliQ) were used.
How to make Extract
1. Moisture content measurement of Phellodendron husk
The samples were placed in a dryer for agricultural products, and the samples were dried at 50 ° C for 24 hours, 24 hours for moisture discharge, and 24 hours for primary drying for 24 hours.
The dried sample is dried in a drying oven at 105 ° C for 3 hours, left in a desiccator for 1 hour, and then weighed. After leaving for 1 hour in the desiccator again, calculate the water content when there is no weight change, and it repeats if the weight continues to decrease. The water content (%) is expressed as a percentage of the weight before drying to the weight before drying, minus the weight after drying.
The drying results are shown in Table 1. The average moisture content of the first dried sample was 12.83%. In the drying process for water content measurement, some of the rosin component melts and some of it flows to the bottom of the container and sticky sticky.
12.83%
0.003366
2. Manufacture of Phellodendron bark extract
Each of the by-products of dried pomace peel, which had been dried in the agricultural product dryer, was ground in a blender and put into a 2 L round-shaped flask (inlet size 24/40) in an amount of 200 g each. Then, 1 L of tertiary distilled water and 50% Reflux extraction was carried out in a constant-temperature water bath at 90 ° C and a cooler at -10 ° C for 4 hours, then the extract was transferred to another vessel, and then 1 liter of the same solvent was added thereto. 2 L of the extract was filtered using a funnel funnel and used for concentration.
The collected extract was concentrated under reduced pressure to a temperature of 55 캜 at 15 brix. The concentrate was frozen at -80 DEG C for 2 hours or more and then lyophilized in a freeze dryer. The lyophilized state was checked every 24 hours, and when the lyophilization was not completed, the ice of the trap was removed and the lyophilized was again dried. After freeze-drying, the weight of the extract including the container was measured, and the weight of the extract was determined by subtracting the weight of the container previously measured, and the extraction yield was calculated. The experimental results are shown in Table 2 below.
(g)
(g)
The yield of hydrothermal extract was 7.55% and the yield of 50% ethanol extract was 17.77%. It was judged that the yield of 50% ethanol extract was high due to the large amount of oil containing the rosin.
When the 50% ethanol extract was condensed in a waste flask under reduced pressure concentration, it was divided into three layers and it was considered to be a water - essential oil - ethanol layer from below.
The part considered as an essential oil layer was about 150 ~ 200ml in volume.
[Experimental Example 1] Cytotoxicity test of extract of rice husk
In order to evaluate the anti - inflammatory and immunological activity of the extracts of Phellodendron chestnut, we examined the cytotoxicity of extracts in the cells used in the experiments.
Raw 264.7 cells (KCLB No. 40071, Korea Cell Line Bank) were subcultured in a 96-well plate at a density of 1 × 10 4 cells / well in an amount of 100 μL. On the next day, the medium was removed, and the water extract and 50% ethanol extract (hereinafter referred to as "sample") of the zucchini by-product prepared in the examples were treated for 72 hours at 37 ° C in a 5% CO 2 incubator. The concentration of each sample was 50, 100, 200, 500, 1000 ㎍ / mL in final concentration. After incubation for 72 hours, the medium was removed and 100 μL of MTT (1 mg / mL) reagent was added. After incubation for 4 to 6 hours in a CO 2 incubator, MTT reagent was removed and 100 μL of DMSO reagent was added After incubation at room temperature (RT), the absorbance (OD) was measured at 570 nm with a microplate reader.
Cytotoxicity test results showed no signs of toxicity by the samples up to the concentration of 1000 ㎍ / ㎖ in the water extract of Picea juncea and 50% ethanol extract, and the cells were increased with increasing concentration. The results are shown in Fig. Fig. 2 shows the results of cytotoxicity measurement of the extract of Yukisugi.
[Experimental Example 2] Evaluation of anti-inflammatory (NO, TNF-α)
NO is known as a very unstable molecule as one of the free radicals and NO is a molecule which is formed by NO 2 , N 2 O 3 , N 2 O 4 , NO 2 - and NO 3 - by superoxide, (L-arginine), nitric oxide synthase (NOS), and NOS are endothelial NOS (eNOS) and neuronal , And inducible NOS (iNOS) induced by NOS (nNOS) and inflammatory factors.
TNF-α is an inflammation-mediated cytokine that acts in vivo alone or with cytokines such as IL-1 and IFN-γ to damage tumor vessels, resulting in tumor necrosis or infection by microorganisms Leads to resistance of the host, and abrupt overproduction has a deleterious effect on the living body and can induce iNOS expression in a wide variety of tissues or organs, tumors, and cell lines
The macrophage acts as a phagocyte that eats the antigen that enters the immune system when it enters the immune system. In this case, the secretion of NO, which is a kind of peroxide secreted when the macrophage is activated, is increased and inflammation is caused by macrophages TNF-α, which causes symptoms and worsens, is overproduced.
In order to measure NO and TNF-alpha, which are the criteria for evaluation of inflammatory activity, the inhibitory effect of LPS (lipopolysaccharide) on the production of NO, which is an inflammatory reaction product, in Raw 264.7 cells, And the amount of TNF-? Produced was measured according to the following steps.
(1) Cell culture
1) Raw 264.7 cells were subcultured in a 96-well plate at 1 × 10 4 cells / well.
2) Overnight After removing media, water extracts and 50% ethanol extracts (hereinafter referred to as "samples") of the zucchini by-products prepared in the Examples were treated for 1 hour at 37 ° C in 5% CO 2 And cultured in an incubator (Incubator). The concentrations of the samples were 50, 100, 200, 500, and 1000 ㎍ / mL in the final concentration.
3) One hour later, LPS was adjusted to 0.5 ug / mL and placed in a group with LPS treatment.
4) After 24 hours, measurements of NO and TNF-a were performed using the supernatant using griess reagent and ELISA kit, respectively.
(2) NO assay: Measurement using a grease reagent
1) A plate was taken out from the incubator for the NO assay.
2) The culture supernatant of the above (1) was transferred into a new 96-well plate in an amount of 70 μl.
3) Griess reagent was taken out from the refrigerator and allowed to stand at
4) 70 μl of sulfanilamide solution was added to a 96-well plate containing 30 μl of the solution.
5) After 30 minutes, 70 μl of NED (N-1-naphthylethylenediamine dihydrochloride) solution was added and left in a dark place for 30 minutes.
6) At the end of the color reaction, the absorbance value (OD) was measured at 520 nm with a microplate spectrophotometer.
As a result, NO production was slightly increased as the treatment concentration was increased when the extract was treated with Raw 264.7 cells alone (green solid line in FIG. 3), but it was not significantly increased compared with LPS treatment, And 50% ethanol extract showed lower NO production than water extract.
The inhibitory effect of NO on LPS-induced NO production (purple solid line 'with LPA' in Fig. 3) inhibited the production of NO at a concentration of 500 and 1000 ㎍ / ㎖ in water extract of PJ % Ethanol (ETOH) extract showed a tendency to inhibit the production of NO but the effect was lower than that of the water extract and the inhibition rate was about 10% lower.
The results are shown in Fig. 3 (results of inhibition of the NO production ability of the extract of Picea magnesia).
(3) Measurement of TNF-a: ELISA assay
1) A capture antibody (capture anti-body (ab)) of ELISA kit (R & D Systems, USA) was diluted with a dilution factor according to the instruction manual and coated on a 96 well nunc plate for ELISA (Nunc cat No. 439454 ) Was dispensed in 100 쨉 l portions at 4 째 C overnight.
2) 200 [mu] l of 0.05
3) 200 μl of 2% skim milk solution was added and blocking was performed at room temperature (RT) for 1 hour.
4) Washing solution was washed twice with 200 ㎕ each.
5) 100 ㎕ of the supernatant of the culture completed in (1) and the standard solution diluted in steps 1) to 4) was dispensed into each well and reacted for 2 hours in a 37 ° C CO 2 incubator .
6) Washing solution was washed 5 times with 200 ㎕ each.
7) detection anti-body (ab) and streptavidin-HRP were diluted with a dilution factor of the protocol in a kit and 100 ㎕ each was dispensed. After incubation at 37 ° C in a CO 2 incubator, For 1 hour.
8) Washing solution was washed by 7 times with 200 ㎕ each.
9) 100 μl of TMB (3,3 ', 5,5'-Tetramethylbenzidine) substrate solution was dispensed and dispensed.
10) 2N H 2 SO 4 as a stop solution was dispensed in an amount of 100 μl, and color development was stopped.
11) The absorbance value (OD) was measured using a microplate spectrophotometer at a wavelength of 450 nm within 40 minutes after stopping the color development.
As a result, TNF-α, which is an inflammatory cytokine, was measured in culture supernatant, and it was confirmed that the amount of TNF-α produced by LPS in a concentration-dependent manner was lowered in the extract of Phellodendra spinach. Similar trend was observed in the 50% ETOH extract, but less than that of the water extract. The results are shown in Fig. 4 (TNF-alpha measurement results of the extract of Phellodendron husk).
The results of (2) and (3) above showed that the water extract of P. junosum inhibited excessive production of NO and TNF-a due to inflammation induced by LPS treatment at a concentration of 500 and 1000 μg / ml, .
Although 50% ethanol extract showed anti - inflammatory activity, it showed less activity than water extract.
[Experimental Example 3] Evaluation of the immunological activity of the extract of the rice husk
IL-6 cytokine production and innate immune responses in Raw 264.7 cell (murine leukemia tumor, macrophage) and murine macrophage induced by extract of Phellodendron chinensis extract and TNF -α was confirmed by the following steps.
(1) Cell culture
1) Raw 264.7 cells were subcultured in a 96-well plate at 1 × 10 4 cells / well.
2) After removal of media after Overnight, water extracts and 50% ethanol extracts (hereinafter referred to as "samples") of zucchini by-products prepared in the Examples were treated for 1 hour at 37 ° C in a 5% CO 2 incubator ). The concentrations of the samples were 50, 100, 200, 500, and 1000 ㎍ / mL in the final concentration.
3) One hour later, for the measurement of IL-6, LPS was adjusted to 5 ug / mL and placed in a group with LPS treatment. (In the case of TNF-α measurement, only the extract is treated alone)
4) After 24 hours, the activity of IL-6 and TNF-α was measured using supernatant using an ELISA kit.
(2) Measurement of IL-6 and TNF-α activity in RAW 264.7 cells: ELIA assay
1) Capture antibody (capture anti-body (ab)) of ELISA kit (BD, IL-6, TNF-α) was diluted in the coating buffer with a dilution factor according to the instruction manual and diluted with 96 well nunc plate for ELISA cat no. 439454) were dispensed at 100 uL and placed overnight at 4 ° C. (Overnight).
2) 200 uL each with washing solution containing 0.05
3) 200 μl of 2% skim milk solution was added and the mixture was blocked at room temperature (RT) for 1 hour.
4) 200 uL each with washing solution.
5) 100 L of the supernatant of step (1) and step diluted standard solutions (1) to 4) were dispensed into each well and incubated in a 37 ° C CO 2 incubator for 2 hours .
6) Washing solution was washed 5 times with 200 uL each.
7) detection anti-body (ab) and streptavidin-HRP were diluted with a dilution factor of the protocol in the kit and 100 uL each was dispensed. After incubation at 37 ° C in a CO 2 incubator, For 1 hour.
8) 200 uL aliquots were washed with washing solution 7 times.
9) TMB substrate solution was dispensed in 100 μl aliquots, and the color development was observed in cows.
10) 2N H 2 SO 4 as a stop solution was dispensed in 100 μl aliquots to stop color development.
11) The absorbance value (OD) was measured using a microplate spectrophotometer at a wavelength of 450 nm within 40 minutes after stopping the color development.
In the supernatant of Raw 264.7 cells, cytokine IL-6 was found to increase with increasing concentrations of water extracts and 50% ethanol extracts. 500 and 1000 ug / mL were similar to positive control (positive control (treated with LPS alone)). In the case of 50% ethanol extract, IL-6 production was increased in a dose dependent manner, And about 40% of positive control group. The results are shown in Fig. Fig. 5 shows the results of measurement of IL-6 activity of the extract of Phellodendrons sp.
When TNF-α was cultured in culture supernatant of Raw 264.7 cells, TNF-α production was increased with increasing concentrations of extracts of Peppermint water and 50% ethanol (ETOH) The extracts showed higher yields than the 50% ethanol extract at the concentrations of 50 and 100 ug / mL. 6 is a graph showing changes in the amount of TNF-?
(3) Analysis of IL-6 activity in mouse murine macrophages: ELISA assay
RAW 264.7 cells are stable in the stable cell line of murine leukemia virus-induced tumors and are thus widely used in basic experiments. However, The murine macrophage, a primer cell, was extracted from the mouse and the reaction in the macrophage was confirmed by the following steps.
1) A 3% TG (thioglycolate medium) aged for 2 days was intraperitoneally administered in 1 mL of a mouse (ICR mouse, Orient Biotechnology, Korea) and left for 4 days.
2) Fill a 10 mL syringe with 10 mL of sterile PBS (Phosphate Buffered Saline).
3) Mice were dislocated by cervical dislocation, and the abdominal cavity was spray-sterilized with 70% ETOH.
4) In the clean hood, the foam and scissors were sterilized by flame to incise the abdominal skin.
5) After the incision, when the dermis layer is removed, the abdominal cavity is washed with PBS in a syringe and the cells are harvested.
6) Centrifugation was performed at 1500 rpm for 5 minutes.
After removing the supernatant, cells were counted and 100 μL of macrophage was added to 96-well plate at 1 × 10 6 cells / well.
8) After Overnight, the media was removed and the samples were treated for 24 hours at 37 ° C in a 5% CO 2 incubator.
9) Final concentration of each sample was 50, 100, 200, 500, and 1000 ㎍ / mL, respectively.
10) After 24 hours, IL-6 activity was measured by the ELISA assay of (2) above using the culture supernatant as a sample for ELISA assay.
As a result of measuring cytokine IL-6 in order to confirm the immunological activity of the extract of Phellodendra spinach on murine macrophage cells, RAW 264.7 cell similar to the above (2) 6, and water extracts showed higher activity. The results are shown in Fig. FIG. 7 shows IL-6 changes in mouse murine macrophages treated with the extract of Picea tulip.
In addition, as in Experimental Example 1, the cytotoxicity test showed no signs of toxicity by the samples up to the concentration of 1000 μg / ml in the water extract of Picea japonica and 50% ethanol, and it was confirmed that the cells increased with increasing concentration .
[Experimental Example 4] Evaluation of proliferation activity of the extract of Picea magna
Spleen is an organs with a lot of lymphocytes. It plays a role of destroying aged red blood cells, eliminating immune complexes and blood cells, and plays a role as a storage depot of lymphocytes. In response to the immune activity, APCs cells such as macrophages secrete various cytokines by stimulating foreign substances or active ingredients, and help T-cells (helper t-cells) Activation leads to the proliferation of IL-2 cytokines and secretory lymphocytes. Whether the extract of Picea junea stimulates the immune cells of splenocytes to increase the proliferation was confirmed by the following steps.
1) The mice were euthanized by dislocation of the cervical vertebrae and then sprayed with 70% ethanol (ETOH) on the left side of the back of the mouse.
2) In the clean hood, the foils and scissors were sterilized by flame, and the skin of the left side of the dorsal portion was incised.
3) After the incision, the spleen was observed through the naked eye and the dermis was incised, and the spleen was stored in the prepared PBS for a short time.
4) The spleen was pulverized using
5) After the pulverization, centrifugation was performed at 1500 rpm for 5 minutes.
6) After removing the supernatant, add 1 mL of sterilized 0.2% NaCl solution and shake well for hemolysis.
7) 9 mL PBS was added and centrifuged at 1500 rpm for 5 minutes.
8) After removal of the supernatant, 1 mL of PBS was added and the debris was removed using an auto pipette.
9) Cells were counted, and then 100 μL of each was dispensed into 96-well plates at 2 × 10 6 cells / well.
10) The concentration of the water extract and 50% ethanol extract (hereinafter referred to as "sample") of the zucchini by-product produced in the examples after maintaining in an incubator at 7 ° C in a 5% CO 2 for 2 hours was 50, 100, 200, 500, and 1000 ㎍ / mL, respectively.
11) After culturing for 3 days, 10 uL of CCK (cell count kit) using WST-1 assay was added, and the OD value was measured at 450 nm after confirming the coloration for 30 to 60 minutes.
The proliferation activity of the extract of Phellinus linteus on the splenocyte obtained from mouse was confirmed to be 10% at the concentration of 1000 ug / mL in the water extract and 50% It was confirmed to happen. This was the same as the result of cytotoxicity test of macrophage RAW 264.7 cell.
The results are shown in Fig. 8 is a graph showing the effect of the extract of Picea magna on the proliferation of splenocytes.
Compared to Experiments 1 to 4, the extracts of water and 50% ethanol of Zizuria japonica showed anti-inflammatory effects by inhibiting excessive production of NO and TNF-α by induction of inflammatory reaction by LPS treatment, IL-6 production, a cytokine that activates NK cells with innate immune system, particularly anti-cancer effect, by reacting with Raw 264.7 cell, which is a stable cell line, and murine macrophage, which is a primer cell, And increased the production of TNF- [alpha], which influences immune cell activity, and thus has an immune activity. It increases the proliferation activity of Raw 264.7 cell and splenocyte, And increased cell proliferation.
Therefore, the extract of Phellodendron japonica has been shown to be effective for antiinflammation, immunological activity and immune cell proliferation.
Hereinafter, a formulation example of a composition having anti-inflammatory or immunostimulating effect according to an aspect of the present invention will be described below, but it may be applied to various other formulations, .
[Formulation Example 1] Health food
Peppermint extract ................... 1000 mg
Vitamin mixture
Vitamin A Acetate ............... 70 ㎍
Vitamin E ....................... 1.0 mg
Vitamin B1 ...................... 0.13 mg
Vitamin B2 ...................... 0.15 mg
Vitamin B6 ........................ 0.5 mg
Vitamin B12 ....................... 0.2 g
Vitamin C .......................... 10 mg
Biotin ............................. 10 μg
Nicotinic acid amide ... 1.7 mg
Folic acid ............................... 50 ㎍
Calcium pantothenate ..................... 0.5 mg
Mineral mixture
Ferrous sulfate ........................ 1.75 mg
Zinc oxide .......................... 0.82 mg
Magnesium carbonate ...................... 25.3 mg
Potassium Phosphate ......................... 15 mg
Secondary Calcium Phosphate ..................... 55 mg
Potassium citrate .......................... 90 mg
Calcium carbonate ........................... 100 mg
Magnesium chloride ...................... 24.8 mg
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with the ingredient suitable for health food as a preferred embodiment, the compounding ratio thereof may be arbitrarily modified.
[Formulation Example 2] Health drinks
Peppermint extract .......................... 1000 mg
Citric acid ................................ 1000 mg
Oligosaccharides ................................ 100 g
Taurine .................................... 1 g
Purified water .................................. Remaining amount
The above components are mixed according to a conventional health drink manufacturing method, and the mixture is stirred and heated at 85 DEG C for about 1 hour, and then the solution is sterilized by filtration.
[Formulation Example 3] Tablets
The granules were formed by mixing 100 mg of Extract of Phellinus crassa, 50 mg of soybean extract, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate and 40 mg of ethanol at 30% Tablets are tableted using a tablet machine.
[Formulation Example 4]
The granules were prepared by mixing 100 mg of Extract of Yuzunkoe, 50 mg of Soybean Extract, 100 mg of Glucose and 600 mg of Starch and 100 mg of 30% Ethanol, and dried at 60 ° C to form granules.
Claims (10)
The extract of Picea japonica promotes the proliferation of immune cells.
The extract of Picea japonica promotes the expression or activity of IL-6.
The extract of Phellodendra japonica inhibits the excessive production of NO and TNF-α.
Wherein said extract is an extract of an aqueous ethanol solution.
Wherein the Picea jute extract is an extract of water.
Wherein the extract of Picea zodiacus is an extract of Picea zooplankton.
The extract of Picea japonica has a composition of 10 / / mL to 100,000 / / mL
Wherein said composition is a cosmetic, food or pharmaceutical composition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140190521 | 2014-12-26 | ||
KR1020140190521 | 2014-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20160079607A true KR20160079607A (en) | 2016-07-06 |
Family
ID=56502534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150084425A KR20160079607A (en) | 2014-12-26 | 2015-06-15 | Composition for anti-inflammation or immuno-stimulation containing an extract of a nut pine cone |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20160079607A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107929358A (en) * | 2017-12-29 | 2018-04-20 | 浙江大晟药业有限公司 | A kind of glossy ganoderma fermentation polyoses grain and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120106848A (en) | 2009-12-23 | 2012-09-26 | 에스.피.엠. 드링크 시스템즈 에스.피.에이. | Movement device, in particular for fluid and/or pasty products |
-
2015
- 2015-06-15 KR KR1020150084425A patent/KR20160079607A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120106848A (en) | 2009-12-23 | 2012-09-26 | 에스.피.엠. 드링크 시스템즈 에스.피.에이. | Movement device, in particular for fluid and/or pasty products |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107929358A (en) * | 2017-12-29 | 2018-04-20 | 浙江大晟药业有限公司 | A kind of glossy ganoderma fermentation polyoses grain and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2329835B1 (en) | Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease | |
KR20160138926A (en) | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions | |
KR101645464B1 (en) | Composition for anti-obesity comprising extract from young barley leaves | |
KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
KR101165716B1 (en) | Compositions for prevention and treatment of allergic disease comprising the fractions from the extracts of Gardenia jasminoides as an active ingredient | |
KR102153414B1 (en) | Composition for improving hair loss and promoting hair growth containing a fermented soybean | |
KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
KR102312675B1 (en) | A composition for improving, preventing and treating of anti-inflammatory, obesity and nonalcoholic fatty liver disease comprising Artemisia Annua extract, Magnolia Obovata Bark extract and its mixed extracts | |
KR102171518B1 (en) | Composition for Preventing or Treating Muscle Atrophy Comprising Lycii Radicis Cortex | |
KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
KR102275055B1 (en) | Composition comprising scutellaria alpina extract | |
KR101692889B1 (en) | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases | |
KR20160079607A (en) | Composition for anti-inflammation or immuno-stimulation containing an extract of a nut pine cone | |
KR20170077640A (en) | Composition for Relaxing Stress and Immunopotentiating Using Red Ginseng Power, etc. | |
KR101865142B1 (en) | Pharmaceutical composition containing combination extract of Spiraea prunifolia, Pyrus pyrifolia and Geum japonicum for prevention and treatment of allergic diease | |
KR101453455B1 (en) | Pharmaceutical composition or healthy food composition containing Oenanthe javanica extract, fractions thereof or isolated flavonoidic compounds for antioxidant and antiobesity activity | |
KR20160114841A (en) | Composition for improvement or treatment of Fat comprising Eucommiae ulmoides Oliv. Bark. extract or Adiponectin isolated therefrom as active ingredient | |
KR20170009470A (en) | Composition for protectng liver cells comprising Schisandra chinensis Concentrate containing elevated amounts of effective ingredients and method for manufacturing the same | |
KR20230036758A (en) | Mixed extraction of enzyme treatment ultrahigh pressure for sleep inducing and insomnia | |
KR101894491B1 (en) | A composition for improving memory or cognitive function comprising a aurantii fructus immaturus supercritical extract as an active ingredient | |
JP6541047B1 (en) | Oral composition | |
KR101503792B1 (en) | Neuroprotective composition comprising extract or fractions of Vaccinium uliginosum as an active ingredient | |
KR20150106187A (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
KR101949557B1 (en) | Composition for immune enhancing activity containingextract of aralia cordata |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application |